Immuron Stock

Immuron Equity

The The Equity of Immuron (IMC.AX) as of Jul 28, 2026 is 8.07 M AUD. In the previous year, The Equity was 12.71 M AUD — a change of -36.51% (lower).

Equity

8.07 MAUD

YoY

-36.51%

Last updated:

In 2026, Immuron's equity was 8.07 M AUD, a -36.51% increase from the 12.71 M AUD equity in the previous year.

Access this data via the Eulerpool API

Immuron Stock analysis

What does Immuron do? Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Immuron's Equity

Immuron's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immuron's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Immuron's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Immuron's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Immuron’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Immuron stock

The Equity of Immuron is 8.07 M AUD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Immuron

All Key Metrics — Immuron